What is FOXO?
FOXO operates at the intersection of artificial intelligence and molecular biology, specializing in the discovery and commercialization of epigenetic biomarkers. By leveraging machine learning to interpret complex biological data, the firm provides actionable longevity insights that serve the insurance, research, and life science sectors. Its core value proposition lies in its ability to transform raw epigenetic data into predictive health models, thereby facilitating more precise underwriting and personalized wellness solutions. As a leader in the longevity research space, FOXO is effectively redefining how healthcare organizations utilize diagnostic capabilities to improve long-term patient outcomes and operational efficiency.
How much funding has FOXO raised?
FOXO has raised a total of $2.1M across 2 funding rounds:
Stock/Share Issuance
$1.5M
Private Equity
$600K
Stock/Share Issuance (2025): $1.5M, investors not publicly disclosed
Private Equity (2025): $600K, investors not publicly disclosed
Key Investors in FOXO
Undisclosed Investor
An institutional capital provider specializing in late-stage growth equity and enterprise-level healthcare infrastructure.
Undisclosed Investor
A strategic partner focused on long-term value creation within the biotechnology and diagnostic services sector.
Undisclosed Investor
A diversified investment firm with a mandate for supporting high-growth, technology-driven healthcare innovations.
What's next for FOXO?
With the recent capital injection, FOXO is positioned to expand its laboratory footprint and enhance its proprietary bioinformatics platform. The strategic roadmap likely involves scaling its diagnostic services to meet the growing demand for data-driven health insights among global insurers and life science partners. By prioritizing the commercialization of its epigenetic platform, the company aims to establish a dominant market share in the predictive health science industry. Future growth will likely be driven by the integration of its diagnostic tools into broader enterprise health ecosystems, further cementing its role as a critical infrastructure provider for the longevity economy.
See full FOXO company page
